Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01251367 · ClinicalTrials.gov registry record · Phase 3
Dysport® Adult Lower Limb Spasticity Follow-on Study
A Phase 3 study, sponsored by Ipsen.
- Completed
- Registry status
- Phase 3
- Development phase
- 352
- Enrollment target
NCT01251367 is a Phase 3 study that has completed, run by Ipsen. The registered enrollment target is 352 participants.
The verdict
NCT01251367, a Phase 3 study, has completed, sponsored by Ipsen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 352 participants
- Enrollment target
Study Summary
The purpose of this research study is to assess the long term safety of Dysport® in hemiparetic subjects with lower limb spasticity due to stroke or traumatic brain injury over repeated treatment cycles.
Interventions
- BIOLOGICAL Botulinum toxin type A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 352 participants |
| Start Date | 2011-06 |
| Est. Completion | 2015-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01251367
The ClinicalTrials.gov registry entry for NCT01251367 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 352 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ipsen, which has 85 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Botulinum toxin type A is the first listed.
NCT01251367 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01251367 about?
NCT01251367 is a clinical study titled "Dysport® Adult Lower Limb Spasticity Follow-on Study". The purpose of this research study is to assess the long term safety of Dysport® in hemiparetic subjects with lower limb spasticity due to stroke or traumatic brain injury over repeated treatment cycles.
What is the current status of trial NCT01251367?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 352 participants. The study started on 2011-06. Estimated completion is 2015-04.
What interventions are being tested in trial NCT01251367?
The interventions under investigation include: Botulinum toxin type A (BIOLOGICAL).
Who is sponsoring clinical trial NCT01251367?
This trial is sponsored by Ipsen, which has 85 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.